Ask the Doctor: Is There a Link Between Albinism and Idiopathic Hypersomnia (IH)?

Is there a link between albinism and idiopathic hypersomnia (IH)? Are GABAA receptor responses involved in both albinism and IH? How have these responses been measured in scientific studies and what are the differences in the mechanisms? We are pleased to have Dr. Amanda Freeman, a PhD neuroscientist and professor at Emory University, answer these questions. Dr. Freeman has extensive experience in researching GABA-related hypersomnias and has previously appeared in our Ask The Doctor feature answering questions about what Emory researchers are looking for in spinal fluid.


I read somewhere that albinism might have an impact on GABA. Is there a link between albinism and idiopathic hypersomnia (IH)?


I am unaware of any research that has examined this possibility directly, but I believe that a link between albinism and idiopathic hypersomnia (IH) is unlikely. Studies of the visual system, which has been studied in the greatest depth, reveal alterations in GABAergic signaling in albinism.3,4 Specifically, albinism is associated with decreased inhibitory GABAA receptor-mediated current,2,8 which is opposite from the increased inhibitory GABAA receptor-mediated currents observed in IH.12

There are important mechanistic differences underlying these findings that should be considered. The studies of GABAA receptor responses in albinism (mentioned above) are based on recordings of brain slices, which allow examinination of the physiological response of an intact neuron. These recordings from albino animals were compared to recordings from pigmented animals under identical conditions. The observed differences indicate that GABAA receptors in the neurons of albino animals function differently than those of pigmented animals. These physiological differences, however, are not the result of alterations in the GABAA receptors; rather, they reflect alterations in the concentrations of chloride ions within the neurons themselves.2,5,6 You may recall from the GABA 102 video that shifts in the ion balance between inside and outside the neuron underlie neuronal activity and that chloride ions play a role in inhibiting neuronal activity. So, while GABAA receptor-mediated currents are altered in albinism, this is an indirect effect of alterations in the physiology of the neuron as a whole that occurs during development.

Alternatively, the study that identified a correlation between altered GABAA receptor-mediated currents and IH was conducted on cells that had been experimentally manipulated to express GABAA receptors. The recorded current conducted through the GABAA receptors under control conditions was compared to the response following exposure to the cerebrospinal fluid (CSF) of individuals with IH. This means that, in contrast to the studies of albinism, the composition of the cells was kept constant, while the response of the GABAA receptors was examined under different conditions. The increased inhibitory response of GABAA receptors when exposed to CSF from people with IH demonstrates that the same cell and the same receptor responded differently under the two conditions.12 Since this experiment was conducted in isolated cells with extremely short exposures to the CSF (<5 seconds), these findings suggest that the altered response resulted directly from an interaction between a substance in the CSF and the GABAA receptor.

Overall, the differences in these experimental designs and findings indicate that an interaction between CSF from people with IH and GABAA receptors results in an increased inhibitory response through different mechanisms than those that lead to the decreased GABAA receptor-mediated current in albinism. So, although albinism does appear to have an impact on GABAA receptor responses, there does not seem to be a link between albinism and IH.


  1. Andersson, H. (2008). Chapter 21 – Clinical Reproductive Endocrinology. In Clinical Biochemistry of Domestic Animals (Sixth Edition), J.J. Kaneko, J.W. Harvey, and M.L. Bruss, eds. (San Diego: Academic Press), pp. 635-662.
  2. Barmashenko, G., Schmidt, M., and Hoffmann, K.P. (2005). Differences between cation-chloride co-transporter functions in the visual cortex of pigmented and albino rats. Eur J Neurosci 21, 1189-1195.
  3. Blaszczyk, W.M., Straub, H., and Distler, C. (2004). GABA content in the retina of pigmented and albino rats. Neuroreport 15, 1141-1144.
  4. Burbridge, T., Choudhury, B.P., and Collard, K.J. (1996). The uptake of gamma-aminobutyric acid and glutamate by synaptosomes from the visual cortex of albino and pigmented rabbits. J Neural Transm (Vienna) 103, 299-305.
  5. Diykov, D., Barmashenko, G., and Hoffmann, K.P. (2008a). Development of chloride homeostasis in albino and pigmented rat visual cortex neurons. Neuroreport 19, 595-598.
  6. Diykov, D., Turchinovich, A., Zoidl, G., and Hoffmann, K.P. (2008b). Elevated intracellular chloride level in albino visual cortex neurons is mediated by Na-K-Cl co-transporter. BMC Neurosci 9, 57.
  7. Hayaishi, O. (2000). Molecular mechanisms of sleep-wake regulation: a role of prostaglandin D2. Philos Trans R Soc Lond B Biol Sci 355, 275-280.
  8. Krause, M., and Hoffmann, K.P. (2009). Shift of chloride reversal potential in neurons of the accessory optic system in albinotic rats. Exp Brain Res 199, 345-353.
  9. Pandey, H.P., Ram, A., Matsumura, H., and Hayaishi, O. (1995). Concentration of prostaglandin D2 in cerebrospinal fluid exhibits a circadian alteration in conscious rats. Biochem Mol Biol Int 37, 431-437.
  10. Pecchi, E., Dallaporta, M., Jean, A., Thirion, S., and Troadec, J.D. (2009). Prostaglandins and sickness behavior: old story, new insights. Physiol Behav 97, 279-292.
  11. Ram, A., Pandey, H.P., Matsumura, H., Kasahara-Orita, K., Nakajima, T., Takahata, R., Satoh, S., Terao, A., and Hayaishi, O. (1997). CSF levels of prostaglandins, especially the level of prostaglandin D2, are correlated with increasing propensity towards sleep in rats. Brain Res 751, 81-89.
  12. Rye, D.B., Bliwise, D.L., Parker, K., Trotti, L.M., Saini, P., Fairley, J., Freeman, A., Garcia, P.S., Owens, M.J., Ritchie, J.C., et al. (2012). Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors. Sci Transl Med 4, 161ra151.
  13. Sadam, H., Pihlak, A., Kivil, A., Pihelgas, S., Jaago, M., Adler, P., Vilo, J., Vapalahti, O., Neuman, T., Lindholm, D., et al. (2018). Prostaglandin D2 Receptor DP1 Antibodies Predict Vaccine-induced and Spontaneous Narcolepsy Type 1: Large-scale Study of Antibody Profiling. EBioMedicine 29, 47-59.
  14. Ueno, R., Ishikawa, Y., Nakayama, T., and Hayaishi, O. (1982). Prostaglandin D2 induces sleep when microinjected into the preoptic area of conscious rats. Biochem Biophys Res Commun 109, 576-582.

EDITOR’S NOTE: If you enjoy this Ask the Doctor series, please consider donating to the Hypersomnia Foundation now. Finally, if you have IH or a related sleep disorder, please join our registry at CoRDS and be sure to update your responses at least yearly.

Disclaimer for Ask The Doctor: The medical information provided is meant for educational purposes only and is not a substitute for professional medical care and advice. Each person is different, and questions about a personal health condition should be discussed with your own healthcare professional.

Share Post

SomnusNooze Home Page

SomnusNooze Editions/Archives

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.